论文部分内容阅读
慢性粒细胞白血病(chronic myeloid leukemia,CML)是一种造血干细胞的恶性克隆增殖性疾病。根据自然病程CML可分为慢性期、加速期和急性期。约85%患者处于慢性期,主要表现为外周血和骨髓中幼稚和成熟髓细胞增多,慢性期相对稳定和对治疗有反应,一般3～4年后发展为加速期,6～18 个月后进入急变期。目前,同种异体造血细胞移植是用匹配的同胞兄弟姐妹或无血缘关系供者的骨髓或外周血干细胞进行移植,已证实是惟一可以治愈CML的手段,但由于供体的缺乏和移植风险大而
Chronic myeloid leukemia (CML) is a malignant clonal proliferative disease of hematopoietic stem cells. According to the natural course of CML can be divided into chronic phase, accelerated phase and acute phase. About 85% of patients are in chronic phase, mainly in peripheral blood and bone marrow increased immature and mature myeloid cells, relatively stable in chronic phase and response to treatment, usually 3-4 years after the development of accelerated period, 6 to 18 months later Into the blazing period. Currently, allogeneic hematopoietic stem cell transplantation is performed with bone marrow or peripheral blood stem cells from matched siblings or unrelated donors and has proven to be the only cure for CML, but due to a lack of donor and a high risk of transplant and